KinCon biolabs develops mutation-specific biosensors that track drug-induced changes in kinase conformations within live cells, enabling precise profiling of drug efficacy and selectivity. Their technology addresses the need for efficient identification of kinase-targeted drug candidates, accelerating the development of effective cancer treatments.
Funding
Funding not disclosed
Founders
Product
Problem
The development of effective kinase-targeted drugs is hindered by the difficulty in efficiently identifying drug candidates that are both efficacious and selective for specific kinase mutations. Traditional methods lack the ability to precisely profile drug-induced changes in kinase conformations within live cells under physiologically relevant conditions.
Solution
KinCon biolabs offers a platform of mutation-specific biosensors that enable the tracking of drug-induced changes in kinase conformations within live cells. These full-length biosensors are expressed in target cell lines, allowing for protein activity measurements under physiologically relevant conditions. The platform facilitates the integration of patient mutations to determine mutation-specific drug efficacies and specificities. KinCon's technology enables systematic analysis through dose- and time-dependent drug profiling in a high-content format, accelerating the identification of effective cancer treatments.
Target Audience
KinCon biolabs primarily targets pharmaceutical companies and research institutions involved in drug discovery and development, particularly those focused on kinase-targeted therapies for cancer and other diseases.
Features
- Full-length biosensors for protein activity measurements in living cells
- Simple integration of patient mutations for precision medicine applications
- Systematic analysis enabling dose- and time-dependent drug profiling
- Ability to track drug-induced changes of protein conformation
- Facilitates the identification of mutation-specific drug candidates